Table 1.
The mean concentrations ± standard deviation of Anthropometric data and biochemical data as lipid profile (LDL, HDL, cholesterol and triglyceride, mmol/L, TG/HDL ratio), aminotransferase (ALT and AST, U/L), apoptosis marker (Fas & FasL pg/ml), glycaemic status (fasting glucose mmol/L & glycated Hb%), kidney function tests and Minerals in the control group and type II diabetic patients.
| Variables | Control n = 100 Mean ± SD |
Patients n = 120 Mean ± SD |
p values |
|---|---|---|---|
| BMI kg/m2 | 23.01 ± 5.19 | 32.9 ± 6.52 | p < 0.01 |
| Duration of the disease/years | – | 7.41 ± 6.01 | – |
| Age/years | 47.25 ± 10.15 | 53.72 ± 9.82 | p = 0.360 |
| LDL mmol/L | 2.66 ± 0.63 | 2.58 ± 0.90 | p = 0.823 |
| HDL mmol/L | 1.55 ± 0.39 | 1.16 ± 0.64 | p < 0.001 |
| Cholesterol mmol/L | 4.58 ± 0.84 | 4.57 ± 1.15 | p = 0.541 |
| Triglycerides mmol/L | 0.71 ± 0.42 | 1.82 ± 1.06 | p < 0.001 |
| TG/HDL-atherogenic dyslipidaemia | 0.52 ± 0.47 | 1.84 ± 1.54 | p < 0.001 |
| Glucose mmol/L | 5.16 ± 0.41 | 9.77 ± 4.03 | p < 0.001 |
| ALT U/L | 34.38 ± 7.3 | 39.35 ± 12.02 | p < 0.001 |
| AST U/L | 20.78 ± 5.56 | 22.51 ± 9.67 | p = 0.154 |
| Glycated Hb % | – | 8.82 ± 1.95 | – |
| Fasting glucose | 5.23 ± 0.73 | 9.66 ± 3.8 | p < 0.001 |
| Na (mmol/L) | 142.71 ± 3.42 | 139.6 ± 4.30 | p < 0.001 |
| Cl (mmol/L) | 103.53 ± 2.22 | 101.77 ± 11.7 | p = 0.065 |
| K (mmol/L) | 4.2 ± 0.38 | 4.15 ± 0.42 | p = 0.299 |
| Ca (mmol/L) | 2.25 ± 0.09 | 2.27 ± 0.100 | p = 0.592 |
| BUN (mmol/L) | 3.79 ± 0.84 | 4.69 ± 3.6 | p = 0.160 |
| Creatinine (μmol/L) | 69.87 ± 10.54 | 72.53 ± 26.70 | p = 0.193 |
| Uric acid (μmol/L) | 231.28 ± 51.43 | 238.29 ± 104.58 | p = 0.59 |
| Fas (pg/ml) | 145.14 ± 23.79 (n = 35) | 149.80 ± 24.41 (n = 40) | p = 0.508 |
| FasL (pg/ml) | 153.90 ± 21.58 (n = 35) | 179.36 ± 20.34 (n = 40) | P < 0.01 |
p < 0.05 consider significance.